Imatinib patient medication instructions

1. Drug name

Common name: imatinib

English name:Imatinib

Trade name: Gleevec (Gleevec), etc.

2. Indications

Imatinib is mainly used to treat the following diseases:

1.Chronic myelogenous leukemia (CML): suitable for chronic phase, accelerated phase and blast phase.

2.Gastrointestinal stromal tumor (GIST): used for cases of recurrence or unresectable after surgical resection.

3.Certain acute lymphoblastic leukemia (ALL): for cases positive for the BCR-ABL fusion gene.

Other tumors caused byBCR-ABL gene mutations: Based on the specific judgment of the doctor.

3. Mechanism of action

Imatinib is a tyrosine kinase inhibitor that works through the following mechanisms:

1.Inhibition ofBCR-ABLtyrosine kinase: Imatinib selectively binds to BCR-ABLtyrosine kinase, blocking its ATP binding site, thereby inhibiting its tyrosine kinase activity.

2.Interfering with cancer cell signal transduction: inhibiting the proliferation and growth of cancer cells by blocking the signal transduction pathways in cancer cells.

3.Promote cancer cell apoptosis: inhibit the proliferation signals of cancer cells and promote cell apoptosis.

4. Pharmacology

1.Drug metabolism: Imatinib is mainly metabolized by the liver in the body, mainly mediated by theCYP3A4enzyme system.

2.Drug excretion: About75% of drugs are excreted through bile, and a small amount is excreted through urine.

3.Half-life: The half-life of imatinib is approximately18 hours, making a once-daily dosing regimen possible.

5. Dosage and usage

1.Adult:

Recommended dose: Generally400 mgonce daily. Specific doses should be adjusted based on the patient's condition and tolerance.

How to take: Take with food to reduce gastrointestinal discomfort. The medicine should be swallowed whole and should not be chewed or crushed.

2.Children:

Recommended dose: Generally based on body weight, initial dose is350 mg/m²once daily. Adjust dosage based on patient response and tolerability.

3.Adjust dosage: If serious side effects occur, the dosage should be adjusted according to the doctor's advice.

6. Side Effects

Common side effects include:

1.Digestive system: nausea, vomiting, diarrhea, loss of appetite.

2.Skin: rash, itching, edema.

3.Hematology system: anemia, leukopenia, thrombocytopenia.

4.Liver: Elevated liver enzyme levels.

5.Cardiovascular: hypertension, heart failure.

6.Others: fatigue, headache, dizziness.

7. Warnings and Precautions

1.Liver function: Monitor liver function regularly, especially when symptoms such as fatigue and jaundice occur.

2.Cardiovascular system: Heart function and blood pressure should be closely monitored in patients with a history of cardiovascular disease.

3.Risk of infection: It may lead to leukopenia. Patients should pay attention to the symptoms of infection and take appropriate preventive measures.

4.Bleeding tendency: If bleeding or bruising occurs, seek medical attention promptly.

5.Medication compliance: Avoid adjusting dosage or discontinuing medication on your own. Any adjustments should be made under the guidance of a physician.

8. Contraindications

1.Allergic reaction: Contraindicated in patients with allergic reactions to imatinib or its components.

2.Pregnant women: Imatinib may be harmful to the fetus, and its use is generally not recommended for pregnant women.

3.Lactating women: Since imatinib may be secreted through breast milk, it is recommended that lactating women stop breastfeeding.

9. Drug interactions

1.CYP3A4Enzyme inhibitors: such as ketoconazole and erythromycin, may increase the plasma concentration of imatinib.

2.CYP3A4Enzyme inducers: such as phenobarbital and rifampin, may reduce the plasma concentration of imatinib.

3.Anticoagulant drugs: such as warfarin, may increase the risk of bleeding.

4.Other drugs: When using other drugs, especially new drugs, you should consult your doctor or pharmacist to ensure there are no potential drug interactions.

10. Medication for Special Populations

1.Elderly: In elderly patients, dose adjustment is usually required based on tolerance and close monitoring for side effects.

2.Hepatic and renal impairment: Patients with impaired liver or renal function should adjust the dose according to specific circumstances, and regularly monitor drug concentration and side effects.

3.Pregnant and breastfeeding women: Imatinib is generally not recommended for use in pregnant women. For women who are breastfeeding, the risks and benefits should be weighed, and cessation of breastfeeding is usually recommended.

Imatinib is a targeted therapy drug suitable for the treatment of various cancers. Understanding its indications, mechanism of action, side effects and precautions will help optimize treatment effects and reduce side effects. Patients should use it under the guidance of a doctor and regularly monitor their physical condition during treatment.